Claims:

1. (Original) A method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma a therapeutically effective amount of a compound which is an EP_4 agonist.

2. (Original) The method of claim 1 wherein said compound is represented by the general formula I;



wherein hatched lines represent the α configuration, a triangle represents the β configuration, a wavy line represents either the α configuration or the β configuration and a dotted line represents the presence or absence of a double bond;

A and B are independently selected from the group consisting of O, S and CH_2, provided that at least one of A or B is S;

D represents a covalent bond or CH_2 , O, S or NH;

X is CO_2R, $CONR_2$, CH_2OR, $P(O)(OR)_2$, $CONRSO_2R$, $SONR_2$ or



Y is O, OH, $OCOR^2$, halogen or cyano;

Z is CH_2 or a covalent bond;

R is H or R^2;

R^1 is H, R^2 , phenyl, or COR^2;

R^2 is C_1-C_5 lower alkyl or alkenyl;

R_3 is benzothienyl, benzofuranyl, naphthyl, or substituted derivatives thereof, wherein the substituents maybe selected from the group consisting of C_1-C_5 alkyl, halogen, CF_3, CN, NO_2, NR_2, CO_2R and OR and R^4 is hydrogen or C_1-C_5 lower alkyl.

3. (Original) The method according to claim 2 wherein said compound is represented by the general formula II;



4. (Original) The method according to claim 3 wherein said compound is represented by the general formula III;



5. (Original) The method of claim 2 wherein Z represents a covalent bond.

6. (Original) The method of claim 2 wherein D represents a covalent bond or is CH_2.

7. (Original) The method of claim 2 wherein X is CO_2 R.

8. (Original) The method of claim 7 wherein R is selected from the group consisting of H, methyl, i-propyl, and n-propenyl.

9. (Original) The method of claim 2 wherein R is H, or n-propenyl.

10. (Original) The method of claim 2 wherein R_1 is H.

11. (Original) The method of claim 2 wherein D is CH_2.

12. (Original) The method of claim 11 wherein R^3 is benzo[b]thienyl, 3-chlorobenzo[b]thienyl or naphthyl.

13. (Cancelled) An ophthalmic solution comprising a therapeutically effective amount of a compound which is EP_4 agonist.

14. (Cancelled) A pharmaceutical product, comprising a container adapted to dispense the contents of said container in metered form; and an ophthalmic solution according to claim 13 in said container.

15. (Original) The method of claim 1 wherein said compound is GR 50209X.